Salix Pharmaceuticals, Ltd. (SLXP) Announces Statistically Significant Results for Budesonide Foam in the Treatment of Active Mild to Moderate Ulcerative Proctitis or Ulcerative Proctosigmoiditis in Two Pivotal Phase 3 Studies
5/22/2013 11:08:44 AM
Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
RALEIGH, N.C.--(BUSINESS WIRE)--Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP) today announced the successful completion and outcome of two pivotal Phase 3 studies to evaluate the efficacy and safety of budesonide foam in the treatment of active mild to moderate ulcerative proctitis (UP) or ulcerative proctosigmoiditis (UPS). In each of the two pivotal Phase 3 studies, a statistically significant proportion of subjects treated with budesonide foam achieved clinical remission compared to subjects treated with placebo foam.
Help employers find you! Check out all the jobs and post your resume.
comments powered by